Erasca, Inc.
ERAS
Jodie situation report
Erasca, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- Existence and terms of the March 2026 clinical trial collaboration and supply agreement with Tango to evaluate ERAS-0015 with vopimetostat in a Phase 1 trial.
Invalidation: The isolated read changes if ERAS's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ERAS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TNGXTango Therapeutics, Inc.partnerMay 11, 2026 ▾
“In addition, we have entered into a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc.”
NVSNovartis AGinvesteeMay 11, 2026 ▾
“Novartis In December 2022, we entered into the Novartis Agreement with Novartis under which we were granted an exclusive, worldwide, royalty-bearing license to certain patent and other intellectual property rights owned or controlled by Novartis to develop, m…”
Depended on by
VSTMVerastem, Inc.competitorMar 4, 2026 ▾
“Competitors that are currently developing RAF and/or MEK inhibitors are Abbvie, AstraZeneca, Bristol Myers Squibb Company, Erasca, Genentech, Novartis AG, and Pfizer.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ERAS is currently a Leader in the organic co-movement group RAS/MAPK Oncology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ERAS; it is not active in the latest market snapshot.